Double Blind, Randomized, Placebo Controlled, Parallel Group Phase IIa Study to Evaluate Safety and Tolerability, Pharmacodynamic Effects and Exploratory Efficacy of an Anti-Angiotensin II Vaccine (CYT006-AngQb) in Patients With Mild to Moderate Essential Hypertension.

Trial Profile

Double Blind, Randomized, Placebo Controlled, Parallel Group Phase IIa Study to Evaluate Safety and Tolerability, Pharmacodynamic Effects and Exploratory Efficacy of an Anti-Angiotensin II Vaccine (CYT006-AngQb) in Patients With Mild to Moderate Essential Hypertension.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Apr 2012

At a glance

  • Drugs CYT 006 AngQb (Primary)
  • Indications Essential hypertension
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Sponsors Cytos Biotechnology
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 24 Jun 2009 Cytos Biotechnology has reported the results of a biochemical analysis of this trial in a company media release.
    • 17 Mar 2009 Secondary endpoint 'Ambulatory blood pressure' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top